ClinicalTrials.gg

Diabetic Neuropathies clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 539 studies for Diabetic Neuropathies across more than 10 countries. 80 are recruiting or about to start. 398 of them are mainly about Diabetic Neuropathies (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its narrower condition Diabetic Foot too: 1,569 studies, 293 open.

ClinicalTrials.gov finds 1,824 studies for Diabetic Neuropathies. How that becomes 538 here

This page counts the studies the registry files under Diabetic Neuropathies, and those it files under no condition that list Diabetic Neuropathiesthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,824Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −983Filed under a narrower condition, counted on its own pageDiabetic Foot 983
  3. −14List Diabetic Neuropathies as a condition, but the registry did not file them under itMost often written as “Diabetic Neuropathy Peripheral” (7), “Peripheral Diabetic Neuropathy” (4), and “Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)” (2). The registry filed them under other conditions only, most often Diabetes Mellitus (6) and Diabetes Mellitus, Type 2 (3).
  4. −291Match it another way52 name it in the title, 2 in a keyword, and 237 by a synonym or other text the search reads.
  5. 536Counted here and found by its search12 of them list Diabetic Neuropathies in their own words; the registry filed them under no condition.
  6. +2
    Counted here, but its search does not find them
  7. 538The count on this page

Status

Completed
343
Recruiting
52
Status unknown
51
Terminated
33
Not yet recruiting
24
Withdrawn
16

Phase

Phase 2
122
Phase 3
77
Phase 4
44
Phase 1
29
Early Phase 1
2

Where

United States
158
Pakistan
45
Germany
37
Egypt
31
Denmark
30
Turkey
28

Who develops what

Add Diabetic Neuropathies to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 2 with this as their studies’ main aim; 1 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
PregabalinEarlier only
Evidence
  • NCT04641273 · Bayer · Phase 2 · comparator · “Pregabalin” · registered Nov 2020
  • NCT01939366 · Tris Pharma, Inc. · Phase 2 · comparator · “Pregabalin” · registered Sep 2013
  • NCT01928381 · AstraZeneca · Phase 2 · comparator · “pregabalin capsules” · registered Aug 2013
  • NCT01863810 · KunWha Pharmaceutical Co., Ltd. · Phase 3 · background · “Lyrica (low dose)” · registered May 2013
  • NCT01345045 · AbbVie · Phase 2 · comparator · “pregabalin” · registered Apr 2011
Viatris Inc.63% of its industry studiesUS: off-patent, 23 generics marketedEU: off-patent, 4 generics authorized00 studies
GabapentinEarlier only
Evidence
  • NCT03749642 · Angelini Pharma · Phase 2 · comparator · “Gabapentin” · registered Nov 2018
  • NCT01263132 · Merck KGaA, Darmstadt, Germany · Phase 3 · comparator · “Gabapentin” · registered Dec 2010
  • NCT00904202 · Keenova Therapeutics plc · Phase 4 · comparator · “Gabapentin + Lidoderm®” · registered May 2009
  • NCT00634543 · Johnson & Johnson · Phase 4 · comparator · “Gabapentin” · registered Mar 2008
Viatris Inc.41% of its industry studiesUS: off-patent, 41 generics marketed00 studies
duloxetineEarlier only
Evidence
  • NCT00844194 · Boehringer Ingelheim · Phase 4 · background · “Duloxetine 60 mg QD” · registered Feb 2009
  • NCT00507936 · AbbVie · Phase 2 · comparator · “Duloxetine” · registered Jul 2007
Eli Lilly and Company84% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 1 Jun 2027 est.Pregabalin · hypera pharma · Phase 3 main aimNCT07712913 Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia — primary endpoint: Difference in the mean pain intensity score 16 weeks after the start of treatment, compared to baseline · 348 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Diabetic Neuropathies studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here SNRIs 15 · Opioids 7

Coming up

31studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger. 6 (12%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (6%) take healthy volunteers.

Recruiting studies that take each age, of 52
AgeWomenMen
104 (8%)4 (8%)
1835 (67%)35 (67%)
3033 (63%)33 (63%)
4041 (79%)41 (79%)
5046 (88%)46 (88%)
6543 (83%)43 (83%)
7534 (65%)34 (65%)
8524 (46%)24 (46%)

Across all 539 studies, recruiting or not: 43% stop at 75 or younger and 16% at 65; 4% take children; 1% are for women only and 1% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Diabetic Neuropathies studies take

Of 25 phase 2 interventional studies under Diabetic Neuropathies, half reached primary completion within 20 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 220 mo14–35 · 25 studies——
Phase 417 mo9–30 · 11 studies——
Interventional, no phase11 mo6–28 · 153 studies—11 mo6–24 · 138 studies
Observational25 mo6–47 · 19 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 539. Browse all 539 → or search them.